keyword
MENU ▼
Read by QxMD icon Read
search

Psoriatic arthritis

keyword
https://www.readbyqxmd.com/read/28091549/urinary-proteomics-can-define-distinct-diagnostic-inflammatory-arthritis-subgroups
#1
Stefan Siebert, Duncan Porter, Caron Paterson, Rosie Hampson, Daniel Gaya, Agnieszka Latosinska, Harald Mischak, Joost Schanstra, William Mullen, Iain McInnes
Current diagnostic tests applied to inflammatory arthritis lack the necessary specificity to appropriately categorise patients. There is a need for novel approaches to classify patients with these conditions. Herein we explored whether urinary proteomic biomarkers specific for different forms of arthritis (rheumatoid arthritis (RA), psoriatic arthritis (PsA), osteoarthritis (OA)) or chronic inflammatory conditions (inflammatory bowel disease (IBD)) can be identified. Fifty subjects per group with RA, PsA, OA or IBD and 50 healthy controls were included in the study...
January 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28090061/umbilical-plaque-in-psoriatic-arthritis
#2
Takao Nagashima, Seiji Minota
No abstract text is available yet for this article.
2017: Internal Medicine
https://www.readbyqxmd.com/read/28089969/changes-in-treatment-patterns-in-patients-with-psoriatic-arthritis-initiating-biologic-and-nonbiologic-therapy-in-a-clinical-registry
#3
Philip J Mease, Tamara Lesperance, Mei Liu, David H Collier, Marc Mason, Sabrina Deveikis, Neil A Accortt
OBJECTIVE: Treatment options for psoriatic arthritis (PsA) have increased and improved in the past decade; treatment patterns in PsA remain poorly understood. Understanding current practices would aid in treatment management of patients with PsA. METHODS: This observational study was based on data from the Corrona registry of adult patients with PsA in North America collected between January 1, 2004, and December 31, 2012. Patients were divided among 3 therapy cohorts: tumor necrosis factor inhibitor (TNFi) monotherapy, methotrexate (MTX) monotherapy, and TNFi and MTX combination therapy...
January 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28089501/effectiveness-of-conventional-disease-modifying-antirheumatic-drugs-in-psoriatic-arthritis-a-systematic-review
#4
Jesús Maese, Petra Díaz Del Campo, Daniel Seoane-Mato, Mercedes Guerra, Juan D Cañete
BACKGROUND: Due to the clinical heterogeneity of psoriatic arthritis (PsA), recommendations have been developed by international groups to guide therapeutic decisions of the rheumatologist. The objective of the current systematic review (RS) was to evaluate the evidence of efficacy of disease-modifying antirheumatic drugs (DMARDs) in PsA. METHODS: Literature search in Medline, EMBASE, Cochrane Library, from 2008 to 2014. We included RS, randomized clinical trials and observational studies, in patients with PsA and an evaluation of efficiency of conventional DMARDs (methotrexate, sulfasalazine, leflunomide), according to the following outcomes: peripheral and axial symptoms; peripheral radiological damage; enthesitis according to power Doppler ultrasound or magnetic resonance imaging (enthesitis count before and after therapy); dactylitis; uveitis...
January 12, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/28085226/radiographic-scoring-instruments-have-moderate-sensitivity-but-high-specificity-for-detecting-change-in-axial-psoriatic-arthritis
#5
Ali Ibrahim, Dafna D Gladman, Arane Thavaneswaran, Lihi Eder, Philip Helliwell, Richard J Cook, Vinod Chandran
OBJECTIVES: There is no widely recognized method to assess axial disease in psoriatic arthritis (PsA). We aimed to determine the sensitivity to change of the Bath Ankylosing Spondylitis (AS) Radiology Index- spine (BASRI-spine), the modified Stoke AS spinal score (mSASSS), the Radiographic AS spinal score (RASSS) and the PsA Spondylitis Radiology Index (PASRI) in Axial PsA (AxPsA). METHODS: Radiographs of 105 patients with AxPsA were retrieved for 2 time points at least 2 years apart and subsequently anonymized...
January 13, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28083616/erap1-and-erap2-gene-variations-influence-the-risk-of-psoriatic-arthritis-in-romanian-population
#6
Olivia M Popa, Marius Cherciu, Laura I Cherciu, Monica I Dutescu, Mihai Bojinca, Violeta Bojinca, Constantin Bara, Luis O Popa
Psoriatic arthritis (PsA) is a chronic inflammatory disorder that belongs to the group of spondyloarthritis (SpA). It was found that single nucleotide polymorphisms (SNPs) of endoplasmic reticulum aminopeptidase (ERAP1 and ERAP2) genes influence the risk of ankylosing spondylitis, the most common form of SpA and the risk of psoriasis. Our purpose was to investigate the possible association of ERAP1 and ERAP2 gene SNPs with psoriatic arthritis susceptibility in Romanian population. Subsequent analyses included patients' subgroups according to HLA-B27 status...
January 12, 2017: Archivum Immunologiae et Therapiae Experimentalis
https://www.readbyqxmd.com/read/28083597/-psoriatic-arthritis-overview-of-drug-therapy-options-and-administration-characteristics
#7
F Behrens, D Thaçi, J Wollenhaupt, K Krüger
Psoriatic arthritis is a chronic inflammatory disease of the musculoskeletal system with association to skin psoriasis and is characterized by variable clinical symptoms with very heterogeneous degrees of disease suffering for patients. Clinical manifestations essentially include alterations to the skin and nails, peripheral arthritis, enthesitis, dactylitis and/or spinal involvement. This variability necessitates an individualized therapy of patients with different therapy targets. Apart from international guidelines no therapy recommendations are available in Germany for treatment of psoriatic arthritis...
January 12, 2017: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/28079929/the-impact-of-age-on-psoriasis-health-care-in-germany
#8
A Trettel, C Spehr, A Körber, M Augustin
INTRODUCTION: Inequality between age groups has been demonstrated in the prescription of biologics, yet systematic real-world data about age-related differences in psoriasis care are missing. OBJECTIVE: To investigate disparities in psoriasis characteristics by age groups and to identify potential impact on psoriasis health care. PATIENTS AND METHODS: Data analysis included 3,615 patients from the German Psoriasis registry PsoBest, which observes adult patients with moderate to severe psoriasis or psoriatic arthritis (PsA) on systemic treatment over a time period of 10 years...
January 12, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28077693/new-grappa-and-eular-recommendations-for-the-management-of-psoriatic-arthritis-process-and-challenges-faced
#9
EDITORIAL
Laura C Coates, Laure Gossec, Sofia Ramiro, Philip Mease, Désirée van der Heijde, Josef S Smolen, Christopher Ritchlin, Arthur Kavanaugh
No abstract text is available yet for this article.
January 11, 2017: Rheumatology
https://www.readbyqxmd.com/read/28076860/efficacy-and-survival-of-systemic-psoriasis-treatments-an-analysis-of-the-swiss-registry-sdntt
#10
Julia-Tatjana Maul, Vahid Djamei, Antonios G A Kolios, Barbara Meier, Justine Czernielewski, Pascal Jungo, Nikhil Yawalkar, Carlo Mainetti, Emmanuel Laffitte, Christina Spehr, Mark Anliker, Markus Streit, Matthias Augustin, Stephan Rustenbach, Curdin Conrad, Jürg Hafner, Wolf-Henning Boehncke, Luca Borradori, Michel Gilliet, Peter Itin, Lars E French, Peter Häusermann, Alexander A Navarini
BACKGROUND: The Swiss psoriasis registry SDNTT (Swiss Dermatology Network for Targeted Therapies) records the long-term safety and effectiveness of systemic treatment regimens for psoriasis. PATIENTS AND METHODS: Patients with moderate to severe psoriasis are included in the SDNTT when treatment with a conventional systemic agent or biologic is initiated that was not previously used by the respective patient. Patients are followed over a 5-year period. Clinical data are obtained every 3-6 months using standardized case report forms...
January 12, 2017: Dermatology: International Journal for Clinical and Investigative Dermatology
https://www.readbyqxmd.com/read/28073691/rapid-dactylitis-resolution-in-a-patient-with-psoriatic-arthritis-after-treatment-with-ustekinumab
#11
Alba Quesada Moreno, Olga Martínez González, Laura Pérez Garrido, Carlos Montilla Morales
No abstract text is available yet for this article.
January 7, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/28052860/increased-prevalence-of-coronary-plaque-in-patients-with-psoriatic-arthritis-without-prior-diagnosis-of-coronary-artery-disease
#12
Jiayun Shen, Ka-Tak Wong, Isaac T Cheng, Qing Shang, Edmund K Li, Priscilla Wong, Emily W Kun, Mei Yan Law, Ronald Yip, Isaac Yim, Shirley Ying, Martin Li, Tena K Li, Chun-Kwok Wong, Tracy Y Zhu, Jack Jock-Wai Lee, Mimi Chang, Alex Pui-Wai Lee, Lai-Shan Tam
OBJECTIVES: To evaluate coronary atherosclerosis in patients with psoriatic arthritis (PsA) and control subjects using coronary CT angiography (CCTA). METHODS: Ninety consecutive patients with PsA (male: 56(62.2%); 50.3±11.1 years) were recruited. 240 controls (male: 137(57.1%); 49.6±10.7 years) without known cardiovascular (CV) diseases who underwent CCTA due to chest pain and/or multiple CV risk factors were recruited for comparison. RESULTS: Patients with PsA and controls were matched in age, gender and traditional CV risk factors (all p>0...
January 4, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28052180/advances-in-psoriasis
#13
Jaclyn Smith, Abigail Cline, Steven R Feldman
Psoriasis treatments range from topical treatments and phototherapy to oral systemic medications and injections. Despite good control of the disease when applying appropriate treatments (according to disease severity, insurance parameters, patient preference, and patients' ability to adhere), continued advancements will allow even better symptomatic control, reduced adverse effects, and patient satisfaction. This review aims to assess traditional and new psoriasis treatments and how to apply them in clinical practice...
January 2017: Southern Medical Journal
https://www.readbyqxmd.com/read/28045646/initial-experience-of-using-dual-energy-ct-with-an-iodine-overlay-image-for-hand-psoriatic-arthritis-comparison-study-with-contrast-enhanced-mr-imaging
#14
Takeshi Fukuda, Yoshinori Umezawa, Shinjiro Tojo, Takenori Yonenaga, Akihiko Asahina, Hidemi Nakagawa, Kunihiko Fukuda
Purpose To determine the feasibility of dual-energy (DE) computed tomography (CT) with an iodine overlay image (IOI) for evaluation of psoriatic arthritis in the hand. Materials and Methods Approval from the institutional ethics committee and written informed consent from all patients were obtained. This prospective study included 16 patients who had psoriasis with finger joint symptoms from January 2015 to January 2016. Contrast material-enhanced (CE) DE CT and 1.5-T CE magnetic resonance (MR) imaging were performed within 1 month of each other...
December 29, 2016: Radiology
https://www.readbyqxmd.com/read/28044348/early-recognition-and-detection-of-juvenile-psoriatic-arthritis-a-call-for-a-standardized-approach-to-screening
#15
E Burden-Teh, K S Thomas, S Rangaraj, J Cranwell, R Murphy
BACKGROUND: National Institute for Health and Care Excellence (NICE) guidelines recommend annual screening for psoriatic arthritis (PsA) in all patients with psoriasis. Currently, no validated assessment tools have been recommended for screening for juvenile PsA (JPsA). AIM: To determine dermatologists' practice when assessing children's joints and explore the challenges dermatologists experience when looking for joint disease, in order to inform future strategies to improve early detection of arthritis...
January 2, 2017: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/28043168/plasma-levels-of-pentraxin-3-in-patients-with-spondyloarthritis
#16
Renato Nisihara, Thelma L Skare, João Otávio Zeni, Henrique Rasera, Karita Lidani, Iara Messias-Reason
CONTEXT: Determining the disease's inflammatory activity in Spondyloarthritis (SpA) is difficult although very important as it is this that drives treatment. OBJECTIVE: To investigate if plasma PTX3 (Pentraxine-3) could act as an inflammatory marker in SpA. METHODS: Eighty one SpA patients (11 with psoriatic arthritis or PsoA and 70 with Ankylosing Spondylitis or AS) and 90 gender and age paired controls were studied for plasma PTX3 levels by ELISA...
January 3, 2017: Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
https://www.readbyqxmd.com/read/28042732/the-potential-utility-of-tildrakizumab-an-interleukin-23-inhibitor-for-the-treatment-of-psoriasis
#17
Zenas Z N Yiu, Richard B Warren
The approved biologic therapies are effective for the treatment of psoriasis, but have limitations. Tildrakizumab has a different mechanism of action and is a humanized immunoglobulin G1κ that binds to the p19 subunit of IL23. Areas covered: Phase I, II and III clinical trials investigated the pharmacokinetics, efficacy, safety and immunogenicity of tildrakizumab for patients with psoriasis. The mean half-life of tildrakizumab is between 20.2 to 28.2 days. Tildrakizumab achieved a PASI 75 of 66% and 74% at week 16 for the doses of 100 mg and 200 mg respectively in a phase IIb randomised clinical trial (RCT), and PASI 75 of 61%/64% and 62%/66% at week 12 for 100 mg and 200 mg respectively in two phase III RCTs...
January 1, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28040421/anti-mda5-dermatomyositis-mimicking-psoriatic-arthritis
#18
Iván Cabezas-Rodríguez, Isla Morante-Bolado, Anahy Brandy-García, Rubén Queiro-Silva, Lourdes Mozo, Francisco Javier Ballina-García
Dermatomyositis causes inflammation and damage of muscle and skin, and sometimes involves internal organs, especially lung parenchyma. Patients with dermatomyositis still represent a diagnostic challenge because of the rarity of this disease and the lack of specificity of some of its cutaneous manifestations. Herein, we describe the case of a patient with dermatomyositis, initially diagnosed as psoriatic arthritis, in which the performance of anti-melanoma differentiation-associated gene 5 (MDA5) antibodies was decisive to establish a definitive diagnosis...
December 28, 2016: Reumatología Clinica
https://www.readbyqxmd.com/read/28038888/biologic-drug-survival-in-israeli-psoriasis-patients
#19
Guy Shalom, Arnon D Cohen, Michael Ziv, Cohen Barak Eran, Ilan Feldhamer, Tamar Freud, Eitan Berman, Shirley Oren, Emmilia Hodak, Lev Pavlovsky
BACKGROUND: Drug survival is defined as the time period of treatment with a certain drug until its cessation. The role of previous exposure to traditional systemic treatments in biologic survival is still unknown. OBJECTIVE: To investigate the drug survival rates of biologic treatments in patients with psoriasis and to identify predictor factors. METHODS: Survival analysis was performed on patients with severe psoriasis who received adalimumab, infliximab, etanercept, and ustekinumab for treatment of psoriasis, drawn from the Clalit Health Services database...
December 28, 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28026823/anti%C3%A2-cytokine-therapy-for-psoriasis-not-only-tnf%C3%A2-%C3%AE-blockers-overview-of-reports-on-the-effectiveness-of-therapy-with-il%C3%A2-12-il%C3%A2-23-and-t-and-b-lymphocyte-inhibitors
#20
Dominika Wcisło-Dziadecka, Martyna Zbiciak, Ligia Brzezińska-Wcisło, Urszula Mazurek
TNF‑α inhibitors - infliximab, etanercept and adalimumab - can be used in the treatment of psoriasis vulgaris and psoriatic arthritis, along with other inhibitors of proinflammatory cytokines, such as interleukin‑12 (IL‑12) and IL‑23. This paper presents the results of research on the use of biological drugs other than the tumor necrosis factor blockers (TNF‑α), namely inhibitors of IL‑12 and IL‑23 (ustekinumab), T‑cell inhibitors (alefacept and efalizumab), B‑cell inhibitors (rituximab), anti‑IL‑17 agents (secukinumab, ixekizumab, and brodalumab) and IL23p19 inhibitors (guselkumab and tildrakizumab)...
December 8, 2016: Postȩpy Higieny i Medycyny Doświadczalnej
keyword
keyword
135
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"